Jennison Associates’s Ligand Pharmaceuticals LGND Stock Holding History

Jennison Associates’s Portfolio LGND Stock Details LGND Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-114,369	Closed	-$6.8M	–	674
2020 Q3	$6.8M	Buy	114,369 +1,907	+2%	+$130K	0.01%	412
2020 Q2	$7.85M	Sell	112,462 -25,232	-18%	-$1.6M	0.01%	400
2020 Q1	$6.25M	Buy	137,694 +6,317	+5%	+$358K	0.01%	376
2019 Q4	$8.55M	Sell	131,377 -2,408	-2%	-$161K	0.01%	393
2019 Q3	$8.31M	Sell	133,785 -203,369	-60%	-$12.8M	0.01%	423
2019 Q2	$24M	Sell	337,154 -18,807	-5%	-$1.39M	0.02%	318
2019 Q1	$27.9M	Buy	355,961 +47,917	+16%	+$3.63M	0.03%	304
2018 Q4	$26.1M	Buy	+308,044	New	+$32.8M	0.03%	312

Other funds holding LGND

William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

CCMLC

Cardinal Capital Management LLC (Connecticut) Greenwich, Connecticut $365M AUM 18.32% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

CCA

Conestoga Capital Advisors Wayne, Pennsylvania $4.6B AUM 16.08% 1-Year Est. Return

SDJVC

St. Denis J. Villere & Co New Orleans, Louisiana $907M AUM 10.61% 1-Year Est. Return

Jennison Associates's LGND Position: Q4 2020 in Review

Jennison Associates sold out of Ligand Pharmaceuticals (LGND) in Q4 2020, closing a stake of 114,369 shares — an estimated $6.8M sold.

Jennison Associates first reported a position in LGND in Q4 2018 and held it in 8 quarters. The position peaked at $27.9M in Q1 2019. 242 funds tracked by Wall St. Rank hold LGND as of Q4 2020.

Jennison Associates reported no remaining Ligand Pharmaceuticals position as of Q4 2020 after selling out during the quarter.
Jennison Associates sold 114,369 Ligand Pharmaceuticals shares in Q4 2020, an estimated $6.8M.
Jennison Associates first reported a position in Ligand Pharmaceuticals in Q4 2018 and held it in 8 quarters.
Jennison Associates's Ligand Pharmaceuticals position peaked at $27.9M in Q1 2019.
242 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q4 2020.

Based on Jennison Associates's 13F filing for Q4 2020, filed 5 Feb 2021.